Preprints
Venkat S and Feigin ME. Alternative polyadenylation characterizes epithelial and fibroblast phenotypic heterogeneity in pancreatic ductal adenocarcinoma. bioRxiv. September 2021 LINK PDF
Doepner M, Natale CA, Lee IY, Venkat S, Kim SH, Katzenellenbogen JA, Katzenellenbogen BS, Feigin ME, Ridky TW. CHRM1 is a Druggable Melanoma Target Whose Endogenous Activity is Determined by Inherited Genetic Variation in DOPA Production. bioRxiv. July 2021 LINK PDF
Venkat S, Tisdale AA, Schwarz JR, Alahmari AA, Maurer HC, Olive KP, Eng KH and Feigin ME. Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma. bioRxiv. August 2019 (Published in Genome Research, 2020) LINK PDF
Peer-reviewed publications
Venkat S, Alahmari AA and Feigin ME. Drivers of gene expression dysregulation in pancreatic cancer. Trends in Cancer. 2021 PDF
Cornwell AC and Feigin ME. Unintended effects of GPCR-targeted drugs on the cancer phenotype. Trends in Pharmacological Sciences. 2020 LINK PDF
Venkat S, Tisdale AA, Schwarz JR, Alahmari AA, Maurer HC, Olive KP, Eng KH and Feigin ME. Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma. Genome Research. 2020 LINK PDF
Insel PA, Sriram K, Wiley SZ, Wilderman A, Katakia T, McCann T, Yokouchi H, Zhang L, Corriden R, Liu D, Feigin ME, French RP, Lowy AM, Murray F. GPCRomics: GPCR expression in cancer cells and tumors identifies new, potential biomarkers and therapeutic targets. Front. Pharmacol. 2018 LINK PDF
Feigin ME*, Garvin T*, Bailey P, Waddell N, Chang DK, Shuai S, Gallinger S, McPherson JD, Grimmond SM, Khurana E, Stein LD, Biankin AV, Schatz MC, Tuveson DA. Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Nature Genetics. 2017 (*Co-first authors) LINK PDF
Feigin ME and Tuveson DA. Challenges and opportunities in modeling pancreatic cancer. Cold Spring Harb Symp Quant Biol. 2017 LINK PDF
Baker L, BeGora M, Yeung FA, Feigin ME, Rosenberg A, Lowe S, Kislinger T, Muthuswamy SK. Scribble is required for pregnancy-induced alveologenesis in the adult mammary gland. J Cell Sci. 129(12), 2307-15, 2016 LINK PDF
Boj SF, Hwang C, Baker LA, Chio IIC, Engle DD, Corbo V, Jager M, Ponz-Sarvise M, Tiriac H, Spector MS, Gracanin A, Oni T, Yu KH, van Boxtel R, Huch M, Rivera KD, Wilson JP, Feigin ME, Öhlund D, Handly-Santana A, Ardito-Abraham CM, Ludwig M, Elyada E, Alagesan B, Biffi G, Yordanov GN, Delcuze B,Creighton B, Wright K, Park Y, Morsink FHM, Molenaar IQ, Rinkes IHB, Cuppen E, Hao Y, Jin Y, Nijman IJ, Iacobuzio-Donahue C, Leach SD, Pappin DJ, Hammell M, Klimstra DS, Basturk O, Hruban RH, Offerhaus GJ, Vries RGJ, Clevers H, Tuveson DA. Organoid models of human and mouse ductal pancreatic cancer. Cell. 160(1-2), 324-38, 2015 LINK PDF
Feigin ME*, Xue B, Hammell MC, Muthuswamy SK*. G-protein-coupled receptor GPR161 is overexpressed in breast cancer and is a promoter of cell proliferation and invasion. PNAS. 111(11), 4191-4196, 2014 (*Co-corresponding authors) LINK PDF
Selected as Science Editor’s Choice (LINK), PNAS Weekly Highlights (LINK)
Feigin ME, Akshinthala SD, Araki K, Rosenberg AZ, Muthuswamy LB, Martin B, Lehmann BD, Berman HK, Pietenpol JA, Cardiff RD, Muthuswamy SK. Mislocalization of the polarity protein Scribble promotes mammary tumorigenesis and is associated with basal breast cancer. Cancer Research. 74(11), 3180-3194, 2014 LINK PDF
Feigin ME. Harnessing the genome for characterization of GPCRs in cancer pathogenesis. (Review) FEBS Journal. 280, 4729-4738, 2013 LINK PDF
Chatterjee S, Seifried L, Feigin ME, Gibbons DL, Scuoppo C, Lin W, Rizvi ZH, Lind E, Dissanayake D, Kurie J, Ohashi P, Muthuswamy SK. Dysregulation of cell polarity proteins synergize with oncogenes or the microenvironment to induce invasive behavior in epithelial cells. PLoS ONE. 7(4):e34343, 2012 LINK PDF
Feigin ME and Muthuswamy SK. Polarity proteins regulate mammalian cell-cell junctions and cancer pathogenesis (Review). Curr Opin Cell Bio. 21(5), 694-700, 2009 LINK PDF
Feigin ME and Muthuswamy SK. ErbB receptors and cell polarity: New pathways and paradigms forunderstanding cell migration and invasion (Review). Exp Cell Res. 315(4), 707-16, 2009 LINK PDF
Bikkavilli RK, Feigin ME and Malbon CC. p38 mitogen activated protein kinase regulates canonical Wnt/β-catenin signaling by inactivation of GSK3β. J Cell Sci. 121(21), 3598-607, 2008 LINK PDF
Feigin ME and Malbon CC. OSTM1 regulates b-catenin/Lef1 interaction and is required for Wnt/b-catenin signaling. Cell Signal. 20(5), 949-57, 2008 (Corresponding author) LINK PDF
Bikkavilli RK, Feigin ME and Malbon CC. G(alpha)o mediates Wnt/c-Jun N-terminal kinase signaling via Dvl 1,3/RhoA family members/MEKK1,4 in mammalian cells. J Cell Sci. 121(2), 234-45, 2008 LINK PDF
Feigin ME and Malbon CC. RGS19 regulates Wnt/beta-catenin signaling through inactivation of G(alpha)o. J Cell Sci.120(19), 3404-14, 2007 (Corresponding author) LINK PDF